About: Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
Creator	Becker, P Bensinger, W Chauncey, T Holmberg, L Maloney, D Rotta, M Sandmaier, B Storb, R Storer, B
Source	PMC
abstract	Allogeneic stem cell transplant for multiple myeloma (MM) is one treatment associated with long-term disease-free survival. The high incidence of treatment-related mortality and relapses, however, are important reasons for controversy about the role of allografting in the management of MM. We reviewed our results of allografting for MM spanning a period of 34 years in order to better define long-term outcomes and identify areas of progress as well as areas requiring improvement. A total of 278 patients received allogeneic marrow or PBSCs after high-dose myeloablative (N=144) or reduced intensity, non-myeloablative (N=134) regimens. In multivariable analysis, adjusting for differences in patient groups, reduced intensity/non-myeloablative transplants were associated with significantly less acute GVHD, lower transplant mortality, better PFS and overall survival. There were no significant differences in relapse, progression or chronic GVHD, when adjusted. In multivariable analysis of patients receiving only non-myeloablative transplants, decreased overall survival and PFS were associated with relapse after a prior autograft and a β2 microglobulin >4.0. Transplant mortality was reduced and only influenced by a prior tandem autograft.
has issue date	2012-02-13(xsd:dateTime)
bibo:doi	10.1038/bmt.2012.1
bibo:pmid	22327126
has license	no-cc
sha1sum (hex)	5ef4ebc78321d5558e10c885ee13712f84b2ec7f
schema:url	https://doi.org/10.1038/bmt.2012.1
resource representing a document's title	Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
has PubMed Central identifier	PMC3376198
has PubMed identifier	22327126
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:5ef4ebc78321d5558e10c885ee13712f84b2ec7f#body_text
is schema:about of	named entity 'improvement' named entity 'areas' named entity 'reasons' named entity 'transplants' named entity 'influenced' named entity 'PFS' named entity 'prior' named entity 'prior' named entity 'ORDER' named entity 'ADJUSTED' named entity 'patient' named entity 'analysis' named entity 'survival' named entity 'high' named entity 'identify' named entity 'mortality' named entity 'relapse' named entity 'define' named entity 'areas' named entity 'reduced' named entity 'disease-free survival' named entity 'PFS' named entity 'relapse' named entity 'autograft' named entity 'non-myeloablative' named entity 'myeloablative' named entity 'relapse' named entity 'GVHD' named entity 'autologous' named entity 'relapse' named entity 'relapse' named entity 'ablative' named entity 'allograft' named entity 'non-myeloablative' named entity 'PFS' named entity 'relapse' named entity 'non-myeloablative' named entity 'chemotherapy regimens' named entity 'myeloablative' named entity 'prophylaxis' named entity 'ablative' named entity 'antibodies' named entity 'transplant recipients' named entity 'cytoreduction' named entity 'ablative' named entity 'University of Washington' named entity 'relapse' named entity 'high-dose' named entity 'PFS' named entity 'allogeneic' named entity 'non-myeloablative' named entity 'autologous' named entity 'non-myeloablative' named entity 'cytogenetic' named entity 'relapse' named entity 'supportive care' named entity 'multivariate analyses' named entity 'allografting' named entity 'autologous' named entity 'ablative' named entity 'ablative' named entity 'diffusion capacity' named entity 'relapse' named entity 'chemotherapy' named entity 'ablative' named entity 'HLA' named entity 'high-dose' named entity 'non-myeloablative' named entity 'Cox regression models' named entity 'radioisotopes' named entity 'allografting' named entity 'ablative' named entity 'melphalan'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software